American Journal of Psychiatric Rehabilitation

Systematic Review Article

Pharmacological Synergy: Systematic Review Of Glp-1 And Gip Receptor Co-Activation By Tirzepatide

Dr. Aishwarya Mishra[1*], Dr. Rajendra Kumar[2], Dr. Aanchal Dwivedi[3], Dr. Kartikey Sharma[4]

[1*](Senior Resident) Department of Pharmacology, Sarojini Naidu Medical College, Agra.
Email: aishwarya.mishra009@gmail.com
[2](Associate Professor) Department of Pharmacology, Autonomous State Medical College, Kanpur Dehat Uttar Pradesh. Email: dr.rajvns@gamail.com
[3](Junior Resident) Department of Pharmacology, Sarojini Naidu Medical College, Agra.
Email: aachal.cms59@gmail.com
[4](Junior Resident) Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj.
Email: sharmakartikey230@gmail.com

***Corresponding Author:** Dr. Aishwarya Mishra
*(Senior Resident) Department of Pharmacology, Sarojini Naidu Medical College, Agra.
Email: aishwarya.mishra009@gmail.com

Abstract
Tirzepatide represents a breakthrough in metabolic therapeutics as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors[1]. This systematic review synthesizes evidence on its pharmacological mechanisms, clinical efficacy, safety profile, and broader implications for type 2 diabetes and obesity management. Drawing from major clinical trials and mechanistic studies, Tirzepatide demonstrates superior glycemic control (mean HbA1c reduction of 1.8-2.6%) and weight loss (up to 25% body weight reduction) compared to single GLP-1 agonists[2,3], attributed to synergistic receptor co-activation. Safety data indicate transient gastrointestinal effects as primary concerns, with low hypoglycemia risk[4]. Future research should explore long-term outcomes and pharmacogenomic influences to optimize personalized therapy.

Keywords: Tirzepatide; GLP-1 receptor; GIP receptor; dual agonism; type 2 diabetes; obesity; incretin mimetics; metabolic syndrome; systematic review

Introduction

The escalating prevalence of type 2 diabetes mellitus (T2DM) and obesity worldwide demands innovative pharmacological interventions that address both glycemic dysregulation and excess adiposity[5]. Traditional therapies, such as metformin and insulin, often fall short in achieving sustained weight loss and comprehensive cardiometabolic benefits. Incretin-based therapies have emerged as a promising class, leveraging the physiological roles of gut-derived hormones like GLP-1 and GIP to enhance insulin secretion, suppress glucagon release, and modulate appetite[6].

GLP-1 receptor agonists (GLP-1RAs), such as Semaglutide, have revolutionized T2DM management by providing robust HbA1c reductions and cardiovascular protection[7]. However, their efficacy is limited by gastrointestinal tolerability and variable weight loss outcomes. GIP, another incretin hormone, complements GLP-1 by promoting insulin sensitivity and potentially mitigating some adverse effects of GLP-1R activation[1]. Tirzepatide, a novel unimolecular dual agonist, uniquely targets both GLP-1 and GIP receptors (GLP-1R and GIPR), offering synergistic effects that amplify metabolic benefits[8].

This systematic review examines the pharmacological synergy of Tirzepatide's dual receptor co-activation. It details the molecular mechanisms, pharmacokinetic properties, clinical trial outcomes on efficacy and safety, and potential future applications. By integrating data from randomized controlled trials (RCTs) like SURPASS and SURMOUNT[2,3], this review highlights how Tirzepatide's biased agonism and receptor affinity differences contribute to superior outcomes compared to monotherapy approaches. Understanding these aspects is crucial for clinicians and researchers aiming to advance precision medicine in metabolic disorders.

Methods

Type of Study: Systematic Review

This systematic review adhered to PRISMA guidelines[9]. A comprehensive literature search was performed across PubMed, Embase, Scopus, Web of Science, and Cochrane Library databases from inception to August 2, 2025. Search terms included "Tirzepatide," "GLP-1 receptor," "GIP receptor," "dual agonism," "type 2 diabetes," "obesity," and combinations thereof. Inclusion criteria encompassed RCTs, meta-analyses, pharmacological studies, and reviews focusing on Tirzepatide's

mechanisms, efficacy, safety, and clinical outcomes in adults with T2DM or obesity. Exclusion criteria involved non-English articles, animal studies, and case reports.

Data extraction covered study design, participant demographics, intervention details, primary outcomes (HbA1c, weight change, adverse events), and mechanistic insights. Quality assessment used the Cochrane Risk of Bias tool for RCTs and AMSTAR-2 for meta-analyses[10]. Quantitative synthesis involved pooling mean changes in HbA1c and weight from key trials, with figures generated to visualize pathways and comparative outcomes. No meta-analytic statistics were computed due to heterogeneity, but descriptive summaries were provided.

Results

Tirzepatide's dual agonism yields multifaceted metabolic effects, as evidenced by mechanistic and clinical data[1,8].

Molecular Mechanism

Tirzepatide, a 39-amino-acid peptide, binds with high affinity to GIPR and moderate affinity to GLP-1R, leading to biased signaling that favors cAMP production over β-arrestin recruitment[1,11]. This results in enhanced glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction[6]



Figure 1: Molecular Pathways Underlying GIP- and GLP-1-Induced Insulin Secretion

- Ligand (GIP or GLP-1) binds to its respective G-protein coupled receptor (GIPR or GLP-1R) on the pancreatic β-cell membrane[6].
- Activation of the Gs protein stimulates adenyyl cyclase, leading to increased production of cyclic AMP (cAMP)[11].
- Elevated cAMP activates protein kinase A (PKA) and EPAC2 (Exchange Protein Directly Activated by cAMP 2)[11].
- PKA closes ATP-sensitive potassium (K_ATP) channels, causing membrane depolarisation[6].
- This depolarisation opens voltage-dependent calcium channels (VDCC), allowing Ca^{2+} influx[6].
- Increased intracellular calcium triggers exocytosis of insulin-containing granules[11].
- In the GLP-1R pathway, additional activation of the PI3K/Akt pathway promotes β-cell survival and growth[6].

Clinical Efficacy and Safety

Pooled data from SURPASS and SURMOUNT trials show tirzepatide's superiority in HbA1c and weight reduction[2,3,12].

Table 2: Comparative Outcomes of HbA1c and Weight Reduction

The following table presents the full dataset, aggregating mean changes from baseline across key trials:

Trial	Treatment	Dose (mg)	Duration (weeks)	Mean HbA1c Reduction (%)	Mean Weight Reduction (%)
SURPASS-1	Tirzepatide	5	40	-1.87	-5.7
SURPASS-1	Tirzepatide	10	40	-1.91	-7.0
SURPASS-1	Tirzepatide	15	40	-2.07	-7.8
SURPASS-1	Placebo	N/A	40	-0.10	+0.9

SURPASS-2	Tirzepatide	5	40	-2.01	-7.6
SURPASS-2	Tirzepatide	10	40	-2.24	-9.3
SURPASS-2	Tirzepatide	15	40	-2.30	-11.2
SURPASS-2	Semaglutide	1	40	-1.86	-6.2
SURPASS-3	Tirzepatide	5	52	-1.93	-7.5 (kg)
SURPASS-3	Tirzepatide	10	52	-2.20	-10.7 (kg)
SURPASS-3	Tirzepatide	15	52	-2.37	-11.9 (kg)
SURPASS-4	Tirzepatide	5	52	-2.24	-7.1
SURPASS-4	Tirzepatide	10	52	-2.43	-9.5
SURPASS-4	Tirzepatide	15	52	-2.58	-11.7
SURPASS-5	Tirzepatide	5	40	-2.11	-8.2
SURPASS-5	Tirzepatide	10	40	-2.40	-10.7

Adverse events were predominantly gastrointestinal, with incidence rates of 20-40% for nausea, resolving over time[4,12]. Hypoglycemia occurred in <5% of cases, lower than insulin comparators[4].

Discussion

Tirzepatide's dual receptor co-activation provides a synergistic platform for metabolic control, surpassing single incretin agonists in efficacy[1,8]. The integration of GIPR signaling enhances insulin sensitivity and may reduce GLP-1R-associated side effects through balanced agonism[11]. Clinical data underscore its potential in high-risk populations, though heterogeneity in trial durations and populations limits generalizability[2,3]. Pharmacokinetic stability supports adherence, but cost and access remain barriers[20].

Conclusion

Tirzepatide's GLP-1 and GIP receptor co-activation marks a significant advancement in treating T2DM and obesity, offering superior glycemic and weight management with acceptable safety[1,12].

Future Interests

Investigations into tirzepatide's role in nonalcoholic steatohepatitis, heart failure, and combination therapies with SGLT2 inhibitors warrant priority[21]. Pharmacogenomic studies could identify responders, and long-term cardiovascular outcome trials are essential[22].

Conflict of Interests

The authors declare no conflicts of interest related to this review.

References

1. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
4. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824.
5. 5. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.
6. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
8. Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396.
9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
10. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

11. Jones B, Buenaventura T, Kanda N, et al. Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat Commun. 2018;9(1):1602.
12. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143-157.
13. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
14. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598.
15. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824.
16. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545.
17. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626.
18. Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341-354.
19. Ghusn W, De la Rosa A, Sacoto D, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982.
20. Alexander JT, Staab EM, Wan W, et al. The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis. J Gen Intern Med. 2022;37(2):415-438.
21. Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393-406.
22. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.